Business
Why the Mesoblast (ASX:MSB) share price is sinking 11% lower
The Mesoblast limited (ASX: MSB) share price has come under pressure on Tuesday after the release of an announcement.
At the time of writing the allogeneic cellular medicines developer’s shares are down 11% to $4.03.
What did Mesoblast announce?
This morning Mesoblast announced the top-line results from the landmark DREAM-HF Phase 3 randomised controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR) in 537 patients with advanced chronic heart failure.
According to the release, after a 30-month follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had a 60% reduction in the incidence of heart attacks or strokes and…
-
General16 hours agoMultiple people missing after house fire in Toolooa, Gladstone
-
Noosa News16 hours agoGrave fears for three people as Gladstone home is engulfed in flames
-
Noosa News12 hours agoFatal traffic incident, Glasshouse Mountains
-
General18 hours agoCopper Coast Council threatens ratepayer with legal action over ‘offensive’ comment